Sodium phenylbutyrate
Clinical data | |
---|---|
Trade names | Buphenyl, Pheburane, Ammonaps, others |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
License data | |
Pregnancy category |
|
By mouth | |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Metabolism | Liver and kidney to phenylacetic acid |
Elimination half-life | 0.8 hours (phenylbutyrate), 1.15-1.29 hours (phenylacetate) |
Excretion | Urine (80-100% as phenylacetylglutamine) |
Identifiers | |
| |
JSmol) | |
| |
| |
(what is this?) (verify) |
Sodium phenylbutyrate, sold under the brand name Buphenyl among others, is a salt of an aromatic fatty acid,
Sodium phenylbutyrate is also a
Structure and properties
Sodium phenylbutyrate is a sodium salt of an aromatic fatty acid, made up of an
Uses
Medical uses
Sodium phenylbutyrate is taken orally or by
Adverse effects
Nearly 1⁄4 of women may experience an adverse effect of amenorrhea or menstrual dysfunction.[4] Appetite loss is seen in 4% of patients. Body odor due to metabolization of phenylbutyrate affects 3% of patients, and 3% experience unpleasant tastes. Gastrointestinal symptoms and mostly mild indications of neurotoxicity are also seen in less than 2% of patients, among several other reported adverse effects.[4] Administration during pregnancy is not recommended because sodium phenylbutyrate treatment could mimic maternal phenylketonuria due to the production of phenylalanine, potentially causing fetal brain damage.[8]
Research
Urea cycle disorders
Sodium phenylbutyrate administration was discovered to lead to an alternative nitrogen disposal pathway by Dr.
Chemical chaperone
In
Histone deacetylase inhibitor
Deriving from its activity as a
Other
Phenylbutyrate has been associated with longer lifespans in Drosophila.[21]
University of Colorado researchers Curt Freed and Wenbo Zhou demonstrated that phenylbutyrate stops the progression of Parkinson's disease in mice by turning on a gene called DJ-1 that can protect dopaminergic neurons in the midbrain from dying. As of July 2011[update] they plan on testing phenylbutyrate for the treatment of Parkinson's disease in humans.[22]
Pharmacology
Phenylbutyrate is a
Sodium phenylbutyrate taken by mouth can be detected in the blood within fifteen minutes, and reaches peak concentration in the bloodstream within an hour. It is metabolized into phenylacetate within half an hour.[4]
References
- ^ "Prescription medicines: registration of new chemical entities in Australia, 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 9 April 2023.
- ^ "Prescription medicines and biologicals: TGA annual summary 2017". Therapeutic Goods Administration (TGA). 21 June 2022. Retrieved 31 March 2024.
- ^ "Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Retrieved 7 April 2024.
- ^ a b c d e f g h i j "Buphenyl- sodium phenylbutyrate tablet Buphenyl- sodium phenylbutyrate powder". DailyMed. 11 March 2020. Retrieved 19 October 2020.
- ^ "Olpruva - sodium phenylbutyrate kit". DailyMed. 22 December 2022. Retrieved 21 January 2023.
- ^ "Ammonaps EPAR". European Medicines Agency. 17 September 2018. Retrieved 3 January 2023.
- ^ PMID 21902286.
- ^ PMID 11148549.
- S2CID 25998574.
- Food and Drugs Administration(FDA). Retrieved 26 October 2013.
- Food and Drugs Administration(FDA) (Report).
- PMID 6243418.
- PMID 7078580.
- PMID 6427608.
- PMID 2014149.
- PMID 2222247.
- PMID 22822398.
- PMID 7517215.
- S2CID 23928373.
- PMID 24167500.
- PMID 11792861.
- PMID 21902286.
The same authors investigated the effects of phenylbutyrate on the accumulation of Parkin-associated endothelin receptor-like receptor (Pael-R), pathologically relevant to the loss of dopaminergic neurons in autosomal recessive juvenile parkinsonism, showing that (i) phenylbutyrate restores the normal expression of Pael-R protein and suppresses ER stress induced by the overexpression of Pael-R; (ii) phenylbutyrate attenuates the activation of ER stress-induced signal transduction pathways and subsequent neuronal cell death; and (iii) phenylbutyrate restores the viability of yeasts that fail to induce an ER stress response under ER stress conditions. These findings lead the author to conclude that phenylbutyrate suppresses ER stress by directly reducing the amount of misfolded protein, including Pael-R accumulated in the ER.[175]
- PMID 23141465.